Patrys Limited · ASX:PAB
Patrys — 6th Annual Australian Biotechnology Summit (July 2008)
23 slides from Patrys's conference presentation, Jul 31, 2008
Slide 1: Natural Human Antibodies to Treat Human Diseases
For personal use only ASX: PAB Natural Human Antibodies to Treat Human Diseases July 2008 Dan Devine Chief Executive Officer
Slide 2: Natural Human Antibodies - Agenda
For personal use only Natural Human Antibodies - Agenda Patrys overview Existing antibody market Natural human antibody based immunity to cancer Patrys y human anti-cancer antibodyy p pipeline p Patrys internal lead candidates Partnered products Milestones 2
Slide 3: Patrys Overview
For personal use only Patrys Overview Product Advantages: Patrys natural human antibodies offer potential potency & safety advantages in $20 billion dollar antibody therapy market Commercial Focus: Patrys products target cancers with mortality rates >80%, where patient, doctor and industry deman
Slide 4: Antibody Market: Well Established & Highly Priced
For personal use only Antibody Market: Well Established & Highly Priced Total Antibody Therapy Sales Antibody Product/Company Values $1,072 M&A Company Values $27.3 US$ Billions US$ Millions $602 $367 $10.4 Product/License Values $149 2004 2005 2006 2007 2008 2009 Preclinical Phase I/II Accepted b
Slide 5: Antibody Product Licensing/Collaborations
For personal use only Antibody Product Licensing/Collaborations* Milestones Stage Upfront Per Licensor Licensee Date Disease Per Antibody Completed Antibody US$* US$* Serono Micromet Dec-04 Phase I Oncology $10,000,000 $138,000,000 Serono NovImmune May-05 Preclinical Autoimmune $2,500,000 $75,000,00
Slide 6: Antibody Company Merger/Acquisition Activity
For personal use only Antibody Company Merger/Acquisition Activity*** Value US Acquiror Acquiree Date Stage Completed Million Lilly AME 2003 $400 Preclinical/Technology MedImmune Cellective 2005 $160 Preclinical/Technology Roche GlycArt 2005 $182 Preclinical/Technology CSL Zenyth 2006 $92 Preclinica
Slide 7: Current Status of Antibody Market
For personal use only Current Status of Antibody Market >100 monoclonal antibodies in various stages of clinical li i l ddevelopment l t 21 approved ((including g 4 anti-cancer antibodies with over US$1 billion in annual sales) Weaknesses: All marketed antibodies contain non-human components
Slide 8: Existing Therapies Bring Little Benefit
For personal use only Existing Therapies Bring Little Benefit 5 Year Mortality Rates for Targeted Cancers (U.S. National Cancer Institute ) 100% 90% Existing treatments have no impact on 80% relative survival in 70% solid tumour cancers 60% 50% Leaves opportunities 40% for Patrys to convert 30%
Slide 9: Significant Competition from 2nd Gen Products
For personal use only Significant Competition from 2nd Gen Products Marketed Antibody > Other Cancer Disease US$1B Sales / Antibodies in T Target t Patrys Antibody the Clinic CD20 Rituxan 10 EGFR Erbitux 12 HER2 H Herceptin ti 9 VEGF Avastin 5 A tib d C Antibody Companies i R Rarelyl C Control t l I
Slide 10: Avastin Case Example
For personal use only Avastin Case Example Avastin Owner Genentech Production Rodent cells grown in fermenter Protein backbone, Components Rodent carbohydrates Mode of Action Kills blood supply pp y to tumours,, and healthy y tissues Approval Failed first trial; Now approved for lung, co
Slide 11: Patrys' Natural Human Antibody Technology
For personal use only Patrys’ Natural Human Antibody Technology Antibody Discovery Antibody Production Cancer Disease Target Do Not Divide, Divide Human X Cancer Short Life Perpetually Lead 2 A tib d Antibody Producing Cell Cell Cancer Human Antibody Producing Patrys Tech X Cancer Cell Proprietary X
Slide 12: Potential Advantages of Natural Human Antibodies
For personal use only Potential Advantages of Natural Human Antibodies Antibodies on Market From Patrys Natural Human Factor Non-Human Sources Antibodies Interfere with function of Do not attack healthy tissues Safer healthy cells and tissues screened Absorbed by healthy tissues – Not absorb
Slide 13: Natural Human Antibody Anti-Cancer Pipeline
For personal use only Natural Human Antibody Anti-Cancer Pipeline Lead Phase I/IIa Discovery Preclinical Selection Human Trial PAT – SC1* Completed Phase I/IIa – Gastric Cancer – AstraZeneca PAT – LM1 Human Trial 2009 – Multiple Cancers – Internal PAT – SM6 Human Trial 2009 – Multiple Cancers – Inte
Slide 14: PAT-SC1: Human Trial for Gastric Cancer
For personal use only PAT-SC1: Human Trial for Gastric Cancer Probability of Survival 100% PAT-SC1 origin: natural human 35 Treated Patients 90% antibody via Patrys’ technology 80% Effective: treated patients had significantly higher survival rate 70% Safe: well tolerated 60% Low dose/cost:
Slide 15: PAT-LM1 and PAT-SM6 Lead Products
For personal use only PAT-LM1 and PAT-SM6 Lead Products Factor PAT-SC1 PAT-LM1 and PAT-SM6 Positive Efficacy established in multiple lab & POC human data animal studies 80% gastric Application to 90% to 98% patients Markets patients across many cancers Safe; Do not react to full panel of healthy Saf
Slide 16: Proprietary Disease Targets – Protected Franchise
For personal use only Proprietary Disease Targets – Protected Franchise Marketed Antibody > Other Cancer Disease US$1B Sales / Antibodies in Target Patrys y Antibody y the Clinic* CD20 Rituxan 10 EGFR Erbitux 12 HER2 Herceptin 9 VEGF A Avastin ti 5 GRP78** PAT-SM6 0 CD55 (SC1)** PAT-SC1 0 CFR-1** CF
Slide 17: Direct Comparison: Avastin Vs. Patrys Human Abs
For personal use only Direct Comparison: Avastin Vs. Patrys Human Abs Marketed Antibody (Avastin) Patrys Natural Human Antibodies Owner Genentech Patrys Production Rodent cells grown in fermenter Human cells Protein backbone, Components 100% human components Rodent carbohydrates Mode o
Slide 18: Key Product Collaborations
For personal use only Key Product Collaborations AstraZeneca – exclusive rights to develop PAT-SC1: AZ has exclusive rights to develop PAT-SC1 P t Patrys earns partnering t i revenue with ith successful f l achievement hi t off milestones by AZ Takeda – covers 5 p product candidates: Inclu
Slide 19: Progress Report on July '07 IPO Objectives
For personal use only Progress Report on July ‘07 IPO Objectives Scale up of production to commercial yields 9 Achieved – 1st to report high yields of natural human antibodies Advance Ad ance PAT PAT-LM1 LM1 & PAT PAT-SM6 SM6 to h human man trials and generate data by Oct ‘09 9 On schedule Adv
Slide 20: New IP: PAT-LM1 v. Metastases
For personal use only New IP: PAT-LM1 v. Metastases Percentage of Animals Weight curve following with Metastases treatment with PAT-LM1 90 10 80 5 70 0 Δ Kg % 60 50 -5 40 -10 30 20 -15 10 -20 0 1 2 3 4 5 6 7 8 No Injection Negative Treatment PAT PAT- Weeks post injection Antibody LM1 LM1 Treated Not
Slide 21: New IP: Lead Candidates Cocktail Approach
For personal use only New IP: Lead Candidates Cocktail Approach Cocktails offer 80 enhanced 1. Relative comparison of anti-proliferative p ability to block 70 effects proliferation of cancer 60 cells (MTT assay) 50 Activitty % 40 2 Represents 2. R the h ffuture off 30 antibody therapies 20 10 3. Com
Slide 22: Upcoming Value-Driving Milestones
For personal use only Upcoming Value-Driving Milestones PAT-SM6 and PAT-LM1 Clinical Plans: Q4CY08: Complete final animal safety studies Q1CY09: Initiate human trials Q4CY09: Phase I/IIa human data Additional Value Drivers Through CY08/CY09: Collaborations: Takeda and AZ partnership resu
Slide 23: Summary
For personal use only Summary Asset A t rich: i h platform, l tf products d t and d cash h Blend of internal and external development Positioned to make an impact p on antibody y market Substantial value to be realized 23
Patrys — 6th Annual Australian Biotechnology Summit (July 2008) on 6ix